More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...
The FDA advances in multiple cancer types, and researchers assess potential impacts of funding freezes on cancer research.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback